Purpose: The ongoing opioid epidemic has claimed more than a quarter million Americans' lives over the past 15 years. The epidemic began with an escalation of prescription opioid deaths and has now evolved to include secondary waves of illicit heroin and fentanyl deaths, while the deaths due to prescription opioid overdoses are still increasing. In response, the Centers for Disease Control and Prevention (CDC) moved to limit opioid prescribing with the release of opioid prescribing guidelines for chronic noncancer pain in March 2016. The guidelines represent a logical and timely federal response to this growing crisis. However, CDC acknowledged that the evidence base linking opioid prescribing to opioid use disorders and overdose was grades 3 and 4.
published opioid prescribing guidelines for chronic noncancer pain patients in March 2016. 10 The CDC guidelines have had swift uptake with state licensing boards adopting them as the standard of care. 11 The guidelines are 1 of the most prominent initiatives by a federal agency and have strong potential for limiting opioid prescribing while maintaining appropriate pain management. However, the guidelines have been subject to criticism. 12, 13 Notably, it has been argued that the guidelines are based on limited evidence, [12] [13] [14] also acknowledged in the guidelines themselves (grade 3 and 4 evidence). 10 Additionally, the majority of studies cited in the guidelines are limited to the association between opioid prescribing with overdose deaths. 10, 14 The guidelines note, however, that while preventing overdose death is paramount, guidelines aimed at preventing prior outcomes like opioid use disorders (OUDs) are equally important in addressing the epidemic. Despite these limitations in the evidence base, the escalating magnitude of the opioid crisis required strong federal action. Therefore, the guidelines were developed by experienced pain medicine physicians and scientists by leveraging pragmatic pain management approaches and the best possible interpretations of the literature available at the time.
The guidelines' emphasis on chronic noncancer pain reflects the concern that most nonmedical use of opioid analgesics occurs in this population and many primary care providers feel inadequately prepared to manage chronic pain while minimizing OUD and overdose risks. 10 However, in doing so, the guidelines were forced to omit cancer pain patients and only made a brief note that 3 to 7 days of opioids might suffice for most acute and postsurgical pain. Moreover, the absence of evidence based on specific clinical subpopulations (eg, women, minorities, acute trauma, and elective surgery) or specific opioid formulations meant that the guidelines adopted a one-size-fits-all approach for the many pain-inducing conditions, regardless of pain etiology and biologic variation among patient subpopulations. Notably, there is a lack of data on effective noncancer pain management among African-Americans, which is concerning given mixed evidence on racial differences in pain and prescribing. [15] [16] [17] These critical research gaps need to be addressed if prescribing behavior is to become more evidence-based.
In this brief review, we examine characteristics of studies cited in the CDC guidelines that specifically addressed the impact of prescription opioids on OUD and overdoses (fatal or nonfatal). We refer to these studies as opioid safety studies and differentiate them from studies evaluating the efficacy of opioids for pain relief. We examine concerns related to internal and external validity in these studies (as noted in the guidelines 10 and a previous systematic review 14 ) and provide recommendations to overcome these limitations in future research, so that refined guidelines can take advantage of a stronger and deeper evidence base.
| METHODS
We examined all the studies cited in the CDC guidelines to identify opioid safety studies for further review. We classified opioid safety studies as those that evaluate the association of opioid prescribing patterns with harmful effects of prescription opioids including fatal and nonfatal overdoses; OUD identified as misuse, abuse, or dependence; or other side effects related to activity, sleep, mood, or bowel dysfunction. We also included studies that examined the association of opioid prescribing patterns with opioid abstinence, emergency department visits, and all cause-mortality. The studies were independently evaluated by 3 co-authors, and information was entered in tabular format by using a common template that included study identifiers, design, data sources, data years, exposures (opioid prescribing), opioid safety outcomes studied, and potential internal and external validity concerns. The resulting data were then reviewed by co-authors as a group, and overall limitations of the evidence base and outline of the results were determined.
3 | RESULTS
| Study characteristics
We found 27 opioid safety studies cited in the CDC guidelines which assessed associations between opioid prescribing and safety outcomes (Table 1) 
KEY POINTS
• Prescribing guidelines for chronic noncancer pain medication has been developed and is being adopted nationwide to mitigate the growing incidence of opioid use disorders and overdose deaths.
• These guidelines have to rely on the current evidence base for prescription opioid safety, which includes studies with multiple internal and external validityrelated limitations.
• Utilization of "big data" resources, superior computing power, and employment of advanced epidemiologic and statistical methods is needed to strengthen the opioid safety evidence base. other properties of these data and studies may result in validity concerns, as discussed below.
| Threats to internal validity
A major internal validity issue in research is lack of exchangeability.
This refers to the imbalance of potential confounders between exposure groups. Lack of exchangeability gives rise to confounding or selection bias. Lack of exchangeability is typically of minimal concern in large, well-conducted RCTs. 20, 22, 30 However, it is a concern in small sample RCTs with selective withdrawals, which was as seen in 3 of the 6 RCTs (Table 2) . 26, 30, 33 Lack of exchangeability is a major concern in observational studies and requires the use of statistical methods to be addressed. This poses several challenges for opioid safety studies. First, depending on the data source used, there may be a lack of confounder information.
For example, PMP and death records may not include diagnostic and substance use disorder histories. While linkage of these 2 sources allows for good exposure assessment 37 and for examining associations between opioid dispensing and overdose deaths, it does not allow us to establish causal relationships between prescription opioids and opioid safety outcomes because of inadequate confounding control. 28, 29, 32, 34, 37 Second, even when confounder information is available from sources like VHA, claims, and EHR, failing to identify and control for all appropriate confounders can lead to biased effect estimates. 19, 21, [23] [24] [25] 27, 35, 36, [38] [39] [40] [41] [42] [43] [44] To illustrate this concept, we developed a directed acyclic graph (DAG) representing the association between prescription opioids and OUD ( Figure 1 ). In Figure 1 , the covariates presented in boxes are potential confounders which, if controlled for, will eliminate measured or known confounding, although there may be other confounders that are unknown or unmeasured . 46 However, several of the observational studies cited in the guidelines failed to account for some or all of these well-known confounders ( Figure 1 47 Fourth, most studies failed to account for time-varying opioid exposure and confounding by indication (eg, patient selection for abuse-deterrent formulations).
In addition to confounding, measurement error due to misclassification of outcome, exposure, or covariates can also lead to a lack of internal validity. 48, 49 For example, researchers frequently express concern that ICD-9/10 codes for opioid dependence and abuse lack sen- (Table 2 ).
An additional source of bias in both observational and randomized studies is selection bias. Such data are only generalizable to the specific geographic catchment area and the practices of physicians and staff at that hospital. Similarly, data generated from the VHA, a single state, or another country, as used in 21 studies cited in the guidelines, [18] [19] [20] [21] [22] [23] [24] [25] [27] [28] [29] [30] [32] [33] [34] 36, 37, [40] [41] [42] [43] might not generalize to the broader US population. Moreover, small sampled studies, even from nationwide sources, may not represent the source population from which the sample arises. 18, 21, 22, 24, 33, 40 Small sample sizes can also lead to nonpositivity (ie, not having exposed and unexposed subjects for each combination of observed confounders) and threaten internal validity. For example, some studies included skin cancer patients but excluded patients with other types of cancer. 22, 23, 27, 31 Previous studies have
shown that White race is associated with a higher incidence of skin cancer, 54 pain, 55 receiving opioids, 56, 57 and experiencing overdose. 
58-64
The emergence of big data science, access to large healthcare databases, modern epidemiological methods, and large-scale computing power provide means to address many of these limitations.
Such methods are already being utilized in HIV, cancer, and pharmacoepidemiology research but remain underutilized in opioid safety or drug use disorder research. Below, we detail some key recommendations and resources that may be useful in planning and conducting future opioid safety research (Table 3 ).
1. Utilize large data resources from multiple states to increase generalizability (external validity). For example, EHR data from multiple health-care systems and large insurance claims data encompassing multiple states represent larger source populations, 5. Consider examining effect measure modification or even biologic interaction 70 due to cancer rather than excluding cancer pain patients or pooling them with noncancer pain patients. This type of research could then inform the need (or lack thereof) for different guidelines for cancer pain and chronic noncancer pain patients. Similarly, it will be valuable to examine effect measure modification for separate clinical subpopulations and acute pain, which could allow specialized guidelines, eg, for postsurgical pain control, acute injuries, and specific diagnoses.
6. Conduct validation studies to quantify the extent of exposure and outcome misclassification 43 in opioid safety studies, especially for claims and EHR data sources. For example, researchers could link claims data to EHR, then conduct EHR chart reviews, followed by patient interviews, to examine misclassification of OUD, as well as exposure misclassification by being able to discern between opioid prescriptions, fills, claims, and actual consumption.
7. Use epidemiologic tools like sensitivity analyses or quantitative bias analyses 71, 72 to examine the level of unmeasured bias (eg, confounding, selection, and misclassification) involved in the generated evidence and its impact on effect estimates. Results from validation studies noted above may be useful to inform parameter estimates used in such analyses. Where possible, sensitivity and quantitative bias analyses should also be used to evaluate and correct covariate misclassification. 48 These recommendations are not exhaustive and do not overcome all limitations present in the opioid safety literature.
Conversely, not all recommendations may be needed for all studies.
Depending on the exact research question, target population, nature of the data, and analytic techniques specific to a study, researchers may need to take additional steps to strengthen internal validity and improve generalizability of results. The CDC guidelines represent the best possible distillation of the available evidence and an eminently reasonable federal response. However, strengthening the evidence base to address the limitations noted in this review will assist in the formulation of any revision of the guidelines, allowing for more refinement of recommendations and potentially even greater prevention impact.
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